BioN­Tech sends $70M to an­oth­er ADC part­ner to go up against Dai­ichi Sankyo in HER3

First, HER2. Now, HER3. That’s the plan of at­tack for BioN­Tech in its ap­par­ent bid to fol­low in the foot­steps of an­ti­body-drug con­ju­gate leader Dai­ichi …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.